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Abstract: The ion-step measuring method was used to determine absolute 
heparin concentrations in PBS and blood plasma with a Ta205 ISFET on to 
which a monolayer of protamine had been immobilized. Heparin is a highly 
negatively charged polysaccharide, which is used clinically to delay the clotting 
of blood. Protamine acts as an affinity ligand for heparin. The response of 
the ISFET system on a step-wise increase in the electrolyte concentration (a 
so-called ion-step) is a transient change of the output voltage, which is related 
to the surface charge density of the ISFET gate oxide. After 2 mins of 
incubation in a plasma sample containing heparin, the amplitude of the 
transient ISFET response to an ion-step showed a linear relation to the 
heparin concentration. In blood plasma, heparin concentrations between 0-3 
and 2-0 Units/ml could be determined with an accuracy of ---0.08 Units/ml. 
Heparin concentrations in different plasma samples of heparinized patients 
were determined and compared with the APTT. No direct relation was found 
between the APTF and the heparin concentration, but this result was not 
surprising. 
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INTRODUCTION 
In one of our previous papers we introduced an 
Ion-Selective Field Effect Transistor (ISFET) 
based heparin sensor using the ion-step measuring 
method (Van Kerkhof et al., 1993). On top of 
the ISFET was mounted a porous membrane, 
consisting of polystyrene beads in an agarose gel, 
in which the affinity ligand was immobilized. 
Although it was possible to determine heparin 
concentrations in buffered solutions with this 
sensor, the results in blood plasma were disap- 
pointing due to a large interfering effect caused 
by other plasma components. In this paper we 
introduce a new approach to this type of heparin 
sensor. The affinity ligand, protamine, is in this 
case directly immobilized at the surface of the 
ISFET; this improves the response time of the 
0956-5663/95/$07.00 © 1995 Elsevier Science Ltd 269 
J.C. van Kerkhof et al. Biosensors & Bioelectronics 
sensor and decreases the effect of the other 
plasma components. With this sensor it is possible 
to determine heparin concentrations in blood 
plasma in the range of physiological importance. 
Heparin 
Heparin is a highly sulphated glycosaminoglycan 
(GAG), found in the liver, lung and other tissues, 
that has several pharmacological properties 
(Nader & Dietrich, 1989). The property of 
heparin that has attracted most attention, and 
resulted in its widespread use, is its ability to 
prolong the clotting time of blood by preventing 
the formation of insoluble fibrin. The anticoagu- 
lant activity of heparin is used in vascular surgery 
and in the treatment of postoperative thrombosis 
and embolism. 
Heparin is defined as a family of polysaccharide 
species, whose chains are made up of alternating 
1,4-1inked and variously sulphated residues of a 
uronic acid and D-glucosamine. The uronic 
acid residues are either L-iduronic acid or D- 
glucuronic acid, and the D-glucosamine r sidues 
are either N-sulphated or N-acetylated (Casu, 
1989). The molecular weight of the heparin 
fragment ranges +5 between 5000 and 30000, 
averaging between 12 000 and 15 000. The polysac- 
charide chains are structurally heterogeneous 
because of an incomplete biosynthetic modifi- 
cation of the precursors of heparin. At physiologi- 
cal pH values the three acidic functional groups 
in heparin are fully dissociated to yield -OSO3, 
-NHSO3, and -COO-  groups, which give rise 
to a highly negatively charged heparin molecule. 
In the blood coagulation process, more than 
ten different proteins are involved, which are 
called coagulation (or clotting) factors and which 
are labelled with roman numerals. Most of these 
proteins are (pro-)enzymes that activate each 
other in a cascade reaction. The result of this 
chain reaction is the formation of the enzyme 
thrombin, which plays a crucial role in the clotting 
process. Thrombin converts the soluble protein 
fibrinogen into insoluble fibrin, which forms the 
basis of a blood clot. To control the blood 
coagulation process, there are many positive 
and negative feedback mechanisms within the 
coagulation process itself, and between the coagu- 
lation process and other processes. One of the 
major ways in which coagulation is controlled is 
by the existence of inhibitory proteins, compo- 
nents of normal blood. The anticoagulant activity 
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of heparin is based on its ability to increase the 
inhibitory effect of some of these inhibitors. 
Antithrombin III (AtIII) is considered to be the 
most important inhibitor of the coagulation 
process and not only inhibits thrombin, as the 
name indicates, but also other coagulation factors. 
However, thrombin and factor Xa are most 
sensitive to inactivation. Heparin binds to AtIII 
and produces a conformational change, thereby 
converting AtIII from a progressive, slow inhibi- 
tor to a very rapid inhibitor. After binding of 
this AtIII-heparin complex to a thrombin or 
factor Xa molecule, heparin dissociates from the 
complex and is reusable (Rosenberg, 1987; Bj6rk 
et al., 1989). Only about one third of the 
molecules in normal heparin preparations are 
able to bind to AtIII and induce anticoagulant 
activity (H66k et al., 1976). The molecules that 
bind to AtIII each contain aunique pentasacchar- 
ide unit, which was found to be the binding site 
for AtIII (Casu, 1989). 
Heparin is one of a variety of drugs extracted 
from natural sources, whose activity can not be 
adequately described or predicted by chemical 
and physical methods. In spite of the enormous 
advances made in recent years concerning knowl- 
edge of the chemical basis for heparin's anticoagu- 
lant activity (Casu, 1989; Petitou, 1989), the 
assessment of heparin for quality control purposes 
by manufacturers and for dosage by clinicians is 
still made in units of biological activity. It has 
been suggested that a value of 8.0/xg per 
activity unit is representative of many heparin 
preparations (Jaques et al., 1990). It is clear that 
for a drug as widely used as heparin, it is of 
crucial importance to ensure that measurements 
of biological activity are properly standardized. 
It is for this reason that the biological activity of 
every commercial heparin preparation is determ- 
ined by comparison with the International Stan- 
dard heparin preparation, of which the activity 
is defined as 1370 Units/ampoule (Barrowcliffe, 
1989). Unlike other drugs in other systems, 
the activity for a given commercial preparation 
relative to the International Standard heparin 
preparation changes depending on the method 
of comparison i  the different blood coagulation 
tests used. Hence, the values will not necessarily 
be the same for any two identical preparations 
compared using different procedures. 
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Monitoring heparin treatments 
A heparin treatment must result in blood heparin 
levels that are sufficient o control thrombosis 
and yet avoid undue risk of bleeding. However, 
the antithrombotic effect and the risk of bleeding 
varies, not only with the dose, but also with the 
individual patient response. This variation in 
response to heparin calls for individualization f
the heparin dose regimen and a careful clinical 
monitoring by laboratory tests (Abildgaard, 
1989). The activated partial thromboplastin time 
(APTT) is the most widely used clinical aboratory 
test for heparin monitoring. In this test, the 
clotting time of a plasma sample is measured 
after the addition of an initiator of the blood 
clotting process. In the presence of this initiator, 
coagulation is greatly accelerated and anticoagu- 
lant activity can then be measured by the delay 
of appearance of a clot, with clotting times 
between 1and 2 min. Unfortunately, the reagents 
and methodology used to perform APTT assays 
vary widely between different laboratories. For 
normal plasma, a typical value of the APT/" is 
of the order of 30 to 40 s. Usually a therapeutic 
range of 1.5-2-5 times the mean value of the 
normal reference range is recommended. By 
translating this APT-f" range to therapeutic hep- 
arin concentration ranges, this has been defined 
as 0-2-0.7 Units/ml (Van Putten et al., 1982) or 
more narrowly as 0.3-0.5 Units/ml (Hirsch, 1986). 
It must be noted however, that the clotting time 
determined by an APTT assay is not only 
dependent on the amount of active heparin, but 
also on the concentration of AtlII and other 
coagulation factors. 
A more specific test for heparin is a chromo- 
genic substrate test. These tests are specific 
peptide substrate tests, which are available for 
thrombin as well as for factor Xa. The principle 
of these tests is the determination of residual 
enzyme activity after the addition of a fixed 
quantity of thrombin or factor Xa to the hep- 
arinized plasma sample and a defined incubation 
time. During this incubation time some of the 
thrombin or factor Xa will be inactivated by 
AtlII, depending on the amount of active heparin 
available. Residual thrombin or factor Xa is 
determined either by the addition of peptide 
substrate to the mixture or by subsampling a
sample from the reaction mixture into the substr- 
ate solution. All the commercially available 
substrates use p-nitroanaline as a chromophore, 
which is released as a result of the reaction with 
thrombin or factor Xa. This release is measured 
by monitoring the change in optical density at 
405 nm. If the test plasma is the only source of 
antithrombin, the result is influenced by the 
AtlII concentration, which can be different from 
patient o patient, and so a combined heparin/ 
antithrombin activity is measured (Teien & Lie, 
1975; B~irtl et al., 1980). If AtlII is added as a 
reagent to the test sample, variations in the 
plasma AtlII concentration of the test sample 
will have minimal influence on the result (Teien 
& Lie, 1977), which in this case is only dependent 
on the concentration of active heparin in the 
plasma. 
In clinical practice no consensus of opinion 
exists concerning which is the most useful test to 
monitor a heparin treatment. It is still unclear 
whether the concentration of active heparin or 
the total "clotting status" (as determined by a 
clotting assay, and dependent on several other 
parameters) is the most important parameter 
(Holm et al., 1987). Patients with low plasma 
AtlII concentration may still have (too) low 
anticoagulant activity, even if the active heparin 
concentration is well within what is usually 
considered as the "therapeutic range". On the 
other hand, if only the clotting time of patients 
with low AtlII concentration is measured, a 
defined therapeutic range may lead to excessive 
heparin dosage and an undue risk of bleeding. 
Moreover, it is found that the plasma AtIll 
concentration regularly decreases during heparin 
treatment (Holm et al., 1985). 
Another important aspect o this discussion is 
the observation of several research groups that 
when injected in vivo heparin generates (extra) 
anticoagulant activity. When heparin was injected 
and subsequently separated from the blood, 
the separated heparin had higher anticoagulant 
activity per mg than the same heparin before 
injection (Levy & Jacques, 1978, Bj6rnsson & 
Wolfram, 1982, Klein et al.,1982). This obser- 
vation indicates important differences between 
the measurement of absolute concentrations of
heparin and the "amount of heparin present" as 
determined by an in vitro coagulation test based 
on a calibration curve. Hence Jaques et al., 
(1990) claim that it is essential to have a method 
to determine the total absolute amount of heparin 
in plasma. 
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An ISFET based heparin sensor using the ion- 
step measuring method 
An aspect of current heparin assays is that 
they each use additional reagents and specific 
equipment and can only be performed in the 
laboratory by skilled personnel. A simple sensor 
system, that can measure directly in a drop of 
whole blood, might therefore be a useful device 
for heparin monitoring. The application of such 
a sensor requires only very small samples (in the 
order of microlitres). If necessary, blood cells 
and platelets could be directly excluded by using 
a filter membrane. Because no sample pre- 
treatment is necessary and no additional reagents 
are used, a simple heparin sensor system might 
be used at the "bedside" and therefore save time 
and money. It is interesting to note in this context 
that approximately 500 million doses of heparin 
are used worldwide each year (Linhardt, 1991), 
which means that at least some tens of millions 
of tests are performed ($5-$10 per test). 
In a previous paper we introduced an ISFET- 
based heparin sensor system using the ion-step 
measuring method (Van Kerkhof et al., 1993). 
The principle of this measuring method was to 
detect a change in charge density in a porous 
membrane which was mounted on top of an 
ISFET (Schasfoort et al., 1990). For the specific 
binding of heparin in the membrane, protamine 
was used as an affinity ligand. Protamine sulphate 
is used clinically to neutralize heparin and to 
counteract i s anticoagulant effects. Protamine is 
a very basic (alkaline) protein with a molecular 
weight of about 4000, typically containing 20 
arginines out of 30 amino acids. It has been 
found that the interaction of protamine and 
heparin consists of a 1:1 pairing of anionic heparin 
sites with cationic protamine sites (Cundall et 
al., 1982). By immobilizing protamine as an 
affinity ligand in this membrane interactions 
between protamine and heparin can be detected 
because these interactions induce a change in 
the charge density in the membrane. Because 
protamine binds all heparin molecules, inde- 
pendent of their anticoagulant activity, the sensor 
system measures total concentrations of heparin. 
To determine the charge density in the mem- 
brane, the ISFET with the membrane is placed 
in a wall-jet cell of a flow-system and an 
equilibrium is established in 10 mM KCI. Sub- 
sequently, the solution which is in contact with 
the ISFET is suddenly replaced (within 100 ms) 
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by a solution with a KCI concentration of 50 or 
100 mM with the same pH. As a response to 
this so-called "ion-step" (at constant pH) the 
ISFET amplifier shows a transient output voltage 
which eventually returns to its original value. 
The amplitude of this voltage peak is a measure 
of the charge density and thus the amount of 
bound molecules in the membrane. 
The ISFET itself also shows a response to 
an ion-step at constant pH and this response 
sometimes interferes with the membrane 
response. Therefore, such ISFET responses were 
investigated in more detail and the mechanism 
was elucidated (Van Kerkhof et al., 1994a). As 
a consequence of the results of this investigation, 
the possibility of direct modification of the ISFET 
surface was investigated with a view to obtaining 
a surface with high affinity for heparin. The first 
successful result was obtained from a treatment 
with an amino functionalized silane coupling 
agent. This results in a coverage with a covalently 
bound, positively charged layer of polysiloxanes 
to which heparin binds through electrostatic 
interaction (Van Kerkhof et al., 1994b). However, 
a better esult is achieved by direct immobilization 
of protamine at the ISFET surface, as described 
in this paper. The immobilized protamine acts 
as an affinity ligand for heparin and the interaction 
can be detected by the ion-step response of the 
ISFET. 
To the knowledge of the authors, only one other 
research group has reported the development of 
a heparin concentration sensor (Ma et al., 1992, 
Yang et al., 1993, Ma et al., 1993). This sensor 
was based on an ion-selective lectrode with 
a polymer membrane, in which a quaternary 
ammonium salt was immobilized that showed a 
significant potentiometric response to heparin. 
The exact mechanism responsible for this 
response is still unclear. The concentration range 
which could be determined in blood plasma was 
reported as 1.0 to 9-8 Units/ml. The sensor can 
therefore be used in surgical procedures where 
doses of 2 to 8 Units/ml are commonly used. 
However, in treatment of post-operative throm- 
bosis and embolism, the therapeutic concentration 
range is 0.2 to 0-7 Units/ml which means that 
this sensor can not be used as an alternative 
for the current assay methods. Therefore, the 
development of a heparin sensor that also covers 
this therapeutic range is still necessary. 
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MATERIALS AND METHODS 
Reagents 
Protamine sulphate (grade X, from salmon) was 
purchased from Sigma Chemical Co. and heparin 
from Organon Teknika (Thromboliquine ®, 5 ml 
ampoules containing 25 000 Units). For some of 
the experiments, the heparin used was made in 
the pharmacy of the "Medisch Spectrum Twente 
(MST)" hospital (sodium salt, 5 ml ampoules, 
5000 Units/ml); this heparin will be referred 
to as "MST heparin". Because the heparin 
concentration of both heparin preparations are 
defined in Units/ml, the heparin concentrations 
in this paper are also given in Units/ml, although 
the response of the sensor is related to absolute 
concentrations. Phosphate buffer was a mixture 
of Na2HPO4 and NaH2PO4 (both products of 
Merck) in the appropriate ratio. HEPES buffer 
was a product of Aldrich Chemical Co. and 
phosphate buffered saline (PBS) tablets were 
purchased from Sigma Chemical Co. Normal 
plasma samples (platelet flee, from a pool of a 
large group of healthy donors) were obtained 
from the laboratory of the MST hospital, along 
with the plasma samples of different hepafinized 
patients of which the APTT was determined 
using a kaolin/cephalin APTT assay (Diagnostica 
Stago). 
Measurement set-up 
The measurement set-up consisted of a flow- 
system in which the flow was controlled by an 
effective pressure (0-1 bar) of nitrogen in the 
two vessels containing the solutions. The resulting 
flow rate was 1-3 ml/min. The ISFET was 
mounted in a wall-jet cell, in which the liquid 
flow was perpendicular to the ISFET surface. A 
cross-section of the wall-jet cell is shown in Fig. 
1. The electrolyte at the surface of the ISFET 
could be replaced within about 0.1 s (ion-step). 
A saturated calomel electrode was used to define 
the potential of the solution. In all experiments 
described in this paper, 10 mM and 100 mM KC1 
solutions were used as the "ion-step" solutions. 
The solutions were buffered with 0.2 mM HEPES 
or 0-1 mM phosphate buffer. The responses of 
the ISFET, connected to a source drain follower, 
were recorded with a Nicolet 310 digital oscillo- 
scope, which can store recorded curves on a 
floppy disk. The output potential of the source- 
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Fig. 1. Cross-section of the wall-jet cell of the flow 
through system. 
drain follower in the case of the equilibrium 
situation in 10 mM KCI was defined as 0 mV. 
For representation purposes, the curves were 
filtered with a software low-pass filter using a 
cut-off frequency of 40 Hz. 
Measurement devices 
ISFETs with a Ta2Os gate insulator were fabri- 
cated in the MESA cleanroom laboratory follow- 
ing the usual ISFET processing steps. The ISFETs 
showed a pH response of -59 mV/pH. The 
protamine was immobilized by physical adsorp- 
tion. The ISFETs were immersed in a solution 
of 10 mg/ml protamine sulphate in PBS for at 
least 24 h, rinsed in 4 M NaCI and subsequently 
stored in a PBS solution. 
Measurement protocol 
Before each incubation period in a heparin 
containing sample, the ISFETs with the immobil- 
ized protamine were characterized by their 
response to an ion-step of 10 to 100 mM KC1. 
Each time the ion-step response had to be 
determined, 3 to 5 responses were successively 
recorded without removing the ISFET, and the 
amplitude of the ion-step response was defined 
as the mean value of the different responses. 
For the determination of heparin concen- 
trations in PBS solutions, small 15 ml vessels 
were used, in which the ISFET was placed for 
two min, during which time the solution was not 
stirred. After incubation, the ISFET was rinsed 
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with PBS and mounted in the wall-jet cell of the 
measurement set-up. The ion-step response was 
recorded and the change in the amplitude, with 
respect o the response before incubation, was 
determined. The ISFETs with the protamine layer 
could be regenerated after each measurement i  
a heparin solution, by rinsing for about 1 min in 
a 4 M NaC1 solution, followed by an equilibration 
period in a PBS solution (varying from 5 min to 
1 h). When recording a calibration curve, which 
gives the change of the ion-step response as a 
function of the heparin concentration, only one 
ISFET was used, which was regenerated after 
each measurement. 
For the determination of heparin concen- 
trations in normal plasma, a test-tube containing 
2 ml of normal plasma was used, to which small 
amounts of a 100 Units/ml heparin solution (in 
0.9% NaC1) were added to obtain the different 
concentrations. The ISFET was incubated in the 
plasma for 2 min (without stirring, with a view 
to future applications where only a drop of blood 
is needed), rinsed in PBS and subsequently the 
ion-step response was determined. The heparin 
concentration of the plasma samples of the 
different heparinized patients was also determined 
by placing the ISFET in a test-tube containing 
0-5 or 1.0 ml of the plasma sample. After 2 min 
the ISFET was rinsed with PBS and the change 
in the amplitude of the ion-step response, with 
respect o the response before incubation, was 
determined. Then 5/xl of a 50 Units/ml or 100 
Units/ml heparin solution was added to yield an 
increase in the heparin concentration of 0.5 
Units/ml. After regeneration in a 4 M NaCI 
solution, the ISFET was used to measure this 
increased heparin concentration, following the 
same procedure. 
RESULTS 
Figure 2 shows some typical ion-step responses 
to 10 to 100mM KCI at pH 7-0. Curve 1 
represents a typical ion-step response of a "bare" 
Ta2Os-ISFET without a protamine layer. Curve 
2 represents a typical ion-step response of an 
ISFET with an adsorbed layer of protamine at 
the gate oxide surface and curve 3 is a typical 
ion-step response of an ISFET with a protamine 
layer after 2 min of incubation in a PBS solution 
containing 0.9 Units/ml heparin. The change in 
the amplitude of the ion-step response after 
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Fig. 2. Typical responses to an ion-step of 10 to 
100 mM KCI at pH 7.0. Curve 1 represents a bare 
ISFET, curve 2 an ISFET with a protamine layer and 
curve 3 an ISFET with a protamine layer after incubation 
in PBS containing 0.9 Units/ml heparin. A~4 is the 
change in amplitude after incubation in a heparin 
solution. 
incubation (curve 3) with respect to the response 
before incubation (curve 2) is referred to as AA. 
The KC1 solutions used for recording curve 1 
were buffered with 0.2 mM HEPES, whereas the 
solutions used for recording curve 2 and 3, 
were buffered with 0-1 mM phosphate buffer. It 
appeared however, that using 0.2 mM HEPES 
instead of 0-1 mM phosphate buffer (or vice 
versa) did not significantly change the response. 
Because the pH of the 10 and 100 mM KCI 
solutions were not exactly the same, curve 2 and 
3 do not return to 0 mV for t ~ ~. ISFETs with 
an adsorbed protamine layer could be stored in 
PBS for at least two weeks without any change 
in the ion-step response at pH 7. 
In Fig. 3, AA is plotted as a function of the 
heparin concentration in a PBS solution. The KC1 
solutions were buffered with 0.1 mM phosphate 
buffer at pH 7.0 and the ISFET was incubated 
for 2 mins in the heparin solution. In this 
case Thromboliquine ® heparin was used. The 
difference between the amplitudes of the 3 to 5 
different responses recorded for each measure- 
ment was about 0.4 mV (mean value ---0.2 mV). 
Because the parameter AA, which is shown in 
Fig. 3, is the difference between the mean value 
(---0-2 mV) of the response before incubation 
and the mean value (---0.2 mV) of the response 
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Fig. 3. The change in amplitude of the ion-step response 
~A after 2 minutes incubation in a PBS solution as a 
function of the heparin concentration (ISFET A). 
after incubation, the accuracy of this parameter 
is ___0.4 mV, as indicated by the error bars. The 
ISFET was regenerated after each measurement 
by rinsing with 4 M NaC1 and used again for the 
following measurement. 
The relation between the change in amplitude, 
AA (mv), of the ion-step response and the 
heparin concentration i  PBS, co (Units/ml), can 
be described by a linear curve fit of the data 
points as shown in Fig. 3. The linear equation is 
given in Table 1 (ISFET code A), together with 
the linear equations of the curve fit of three 
other ISFETs with a protamine layer, which were 
used to determine AA as a function of the 
heparin concentration i  PBS. 
Figure 4 shows AA (10 to 100 mM KCI, 
0-1 mM phosphate buffer, pH 7-0) as a function 
of the heparin (Thromboliquine ®)concentration 
in normal plasma, in which the ISFET was 
incubated for 2 min. The same ISFET (code A) 
and the same solutions were used as for the 
measurement of the heparin concentration i
PBS. The error bars indicate the accuracy of AA 
as explained in the legend to Fig. 3. The relation 
between the change in amplitude, AA (mV), and 
the heparin concentration i plasma, c o (Units/ 
ml), can again be described by a linear curve fit 
of the data points, starting from 0-25 Units/ml, 
and the linear equation is given in Table 1 (code 
A). Note the difference in offset and slope in 
comparison with the curve fit of the measurements 
in PBS. The ISFET with code B was also used 
to determine heparin concentrations in normal 
plasma and the linear equation of the curve fit 
of the results is given in Table 1. For this ISFET, 
also note the difference in offset and slope in 
comparison with the curve fit of the measurements 
in PBS. 
Figure 5 shows AA as a function of the heparin 
concentration in normal plasma, determined with 
another ISFET (code D). In this case the ion- 
step responses were recorded at pH 7-4 and 
the KC1 solutions were buffered with 0-2 mM 
HEPES. MST heparin was used. The linear curve 
fit is again given in Table 1. This curve was used 
as a calibration curve for the measurement of
the heparin concentration i  plasma samples of 
several patients who where heparinized with MST 
heparin. In Table 2 the heparin concentrations 
of these samples are presented as determined 
with the ion-step measuring method using Fig. 5 
as a calibration curve. After each measurement 
of the heparin concentration f a specific sample, 
0-5 Units/ml heparin were added to the sample 
and the concentration was measured again. These 
values are also given in Table 2. Thirteen different 
samples were tested, and in nine of the samples 
the increase in the heparin concentration of 0-5 
Units/ml was correctly measured within the range 
0-5 -+ 0.07 Units/ml. In the other 4 samples the 
measured increase was less than the added 0.5 
Units/ml. 
The ISFET used for these experiments (code 
D) was regenerated more than fifty times. The 
amplitude of the calibration response, which was 
recorded after each regeneration procedure, only 
changed by about 2 mV. 
Table 2 also shows the values for the APTT 
of the different plasma samples. Figure 6 shows 
the relation between the APTT and the measured 
heparin concentrations for the nine samples in 
which the sensor correctly measured the increase 
of 0-5 Units/ml as well as for the other 4 samples. 
It can be seen that no clear relationship exists 
between the APTT value and the measured 
heparin concentration. 
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TABLE 1 Linear curve fits of heparin concentration measurements of
different ISFETs. The ion-step responses of ISFET D were recorded at 
pH 7.4 and MST heparin was used. The other ISFETs were measured at 
pH 7.0 and Thromboliquine was used as heparin. AA is the change in 
amplitude after incubation (mV), Cb is the heparin concentration i PBS 
and Cp the heparin concentration i normal plasma (both in units/ml). 
ISFET Linear curve fit of heparin 
code concentration measurement 
in PBS 
Linear curve fit of heparin 
concentration measurement 
in normal plasma 
A 
B 
C 
D 
AA = --0.15 + ll'0Cb (fig. 2) 
AA = --0"30 + 10"6% 
AA = -0"25 + l l '6cb 
AA = -0"01 + 11"3% 
AA = 2.53 + 6.10% (Fig. 3) 
AA = 2-38 + 4.51Cp 
AA = 3.17 + 4.86Cp (Fig. 4) 
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Fig. 4. The change in amplitude of the ion-step response 
~,4 after 2 minutes incubation in normal plasma as a 
function of the heparin concentration (ISFET A). 
DISCUSSION AND CONCLUSIONS 
The mechanism behind the ion-step response of 
a "bare"  ISFET  as shown in Fig. 2, curve 1, has 
already been descr ibed (Van Kerkhof ,  1994a) 
but will be briefly reviewed. 
The interface between the ISFET  and the 
solution is descr ibed by the acid-base equi l ibr ia 
at the amphoter ic  surface of the Ta2Os-gate 
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Fig. 5. The change in amplitude of the ion-step response 
A,4 after 2 minutes incubation in normal plasma as a 
function of the heparin concentration (ISFET D). 
Calibration curve for the experiments shown in Table 
2. 
oxide. The surface OH groups can act as proton 
donors as well as proton acceptors,  yielding a 
charge density, o- (in C/cm2), at the surface. 
or = q ([Ta - OU~-] - [Ta - O- ] )  (1) 
The pH where tr = 0 is cal led the point  of zero 
charge, pHpzc, which for Ta205 lies around pH 
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TABLE 2 Results of measurements in 
samples of heparinized patients. 
plasma 
Measured Measured change APTT (seconds) 
heparin (in Units/ml) 
concentration after addition of 
(Units/ml) 0.5 Units/ml 
1.18 0.47 141 
1.22 0.51 86 
1.00 0.45 144 
0.85 0.49 156 
1.30 0.47 73 
1.00 0.47 92 
1.02 0.43 55 
0.79 0.54 93 
0.97 0.43 87 
1.06 0.35 134 
1.06 0.37 67 
0.75 0.23 72 
0.95 0.27 119 
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Fig. 6. The APTT as function of the measured heparin 
concentration for the different plasma samples of 
heparinized patients. The crosses (+) represent the 
samples in which the addition of 0.5 Units/ml was 
correctly measured, and the triangles (A) represent the 
other samples. 
3; this means that at pH 7 the Ta205 surface is 
negatively charged. The relation between the 
surface charge, tr, and the surface potential, ~ ,  
is given by: 
= q'Ca, (2) 
ISFET based heparin sensor 
where Cdl is the double layer capacitance (in F/ 
cm2). 
The ISFET measures the surface potential, ~,  
with respect to the bulk potential, which is 
defined by the reference lectrode. This potential 
follows from the Boltzmann equation: 
[H~+ ] = [H~ ] exp (-k--kq~) (3) 
where [H+~] is the proton concentration at the 
ISFET surface and [H~] the proton concentration 
in bulk solution. The combination of the large 
number of OH surface sites (about 1015/cm2), 
the chemical equilibria of the acid-base reactions 
and the relative low value of the double layer 
capacitance (maximum 20/xF/cm2), makes the 
Ta205 oxide surface act as a very good buffer 
for H+~, which results in an almost constant pH 
at the surface (pHs). Consequently, the surface 
potential, qt, changes with -59 mV/pHb (van 
Hal et al., 1994). 
Equations 1 to 3 describe the statical behaviour 
of the ISFET in thermodynamical equilibrium. 
However, the transient response to an ion-step 
cannot directly be described by these equations. 
To elucidate the mechanism behind these 
responses, a dynamical simulation model was 
developed based on the Nernst-Planck and Pois- 
son equations, which are solved by a finite 
difference procedure. The chemical equilibria at 
the ISFET surface are incorporated in this model 
of the ISFET, together with a stagnant layer in 
which ion-transport is caused only by diffusion 
and migration. With this model it is possible to 
understand the dynamic mechanism and verify 
the experimental results (Van Kerkhof et al., 
1994a). 
After an ion-step, Cdl increases very fast due 
to a sudden increase in the diffuse capacitance, 
which results in a decrease in the absolute value 
of the surface potential ~ ,  according to eqn. (2). 
According to the Boltzmann equation (3), the 
H + concentration will tend to decrease because 
of the decreased ~.  However, the oxide surface 
acts as a very good buffer for H + and will keep 
the H + concentration constant by dissociating 
Ta-OH groups. This will change tr until a new 
equilibrium is reached, when O/Col (~- ~) has 
the same value as before the ion-step. The time 
constant of adapting ~r by dissociating Ta-OH 
groups is determined by the diffusion of the H + 
ions and the buffer capacity of the electrolyte. 
A thick stagnant layer and/or a low buffer 
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capacity will delay the establishment of a new 
equilibrium. This was indeed observed in exper- 
iments that were in agreement with the simulation 
results. 
If the double layer capacitance changes, as a 
result of an ion-step of 10 to 100 mM KC1, from 
Cdn to COl2, the theoretical maximum change in 
directly after the ion-step (assuming that or is 
not changing yet) is: 
O r Or 
AX I /ma x = %I/2 - -  x I f  1 - -  (4) 
Cdl2  Cd l l  (cd. ) 
= th \Ca]2 - 1 
The double layer capacitance can be calculated 
using the Gouy-Chapman-Stern model and 
depends on the electrolyte concentration and on 
the potential • across the double layer. Figure 
7 show the values of Can (in 10 mM) and Call 2 
(in 100 mM), as well as the ratio CdI1/Cdl2, as a 
function of the potential ~,  calculated according 
to the Gouy-Chapman-Stern model; a constant 
Stern capacity of 20/zF/cm 2 is assumed (Bard & 
Faulkner, 1980). 
At pH 7, the surface potential, ~,  of a Ta205 
ISFET (pHpzc = 3) is (7 -3)  × -59  = -236 inV. 
The double layer capacitance at 10 mM KC1 is 
12.7 /xF/cm 2, which results, according to eqn. 2 
in a surface charge, or, of -3 .00 × 10 -6 C/ 
cm 2, corresponding with 1.87 × 1013 negatively 
charged groups per cm 2. The value of Cd~ at 
18 1.0 
E 
o 
0 
16 
14 
12 
10 
< 
/ 
/ 
J 
\ __ .__ Cd l l /Cd l  a f > 
1 
0.9 
0.8 I 
0 
0.7 
0.6 
0.5 
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Fig. 7. The double layer capacitance, Cdl, as a function 
of the potential qt across the double layer. Can is the 
capacitance in 10 mM KCI, Caz2 the capacitance in 
100 mM KCl (left Y-axis) and Cdu/Cm2 represents the 
ratio of the two capacitances as used in equation 4 
(right Y-axis). 
278 
100 mM KC1 is 16-1 /~F/cm 2, which gives a value 
of 50 mV for A'kI/ma x as defined by eqn. 4. 
Because of an insufficient time separation 
between the changes in Cdl and or, which is 
caused by the stagnant layer related to the buffer 
capacity of the solution, the real value of the 
amplitude of the ion-step response is smaller 
than the theoretical maximum. This effect was 
clearly observed in the simulation results (Van 
Kerkhof et al., 1994a). The experimental result 
of 27 mV (Fig. 2) implies that the response 
reaches 54% of its maximum value due to the 
insufficient ime separation between the changes 
in Co~ and or. 
Immobilization of protamine by physical 
adsorption will result in a coverage with a 
maximum thickness of a few monolayers, but 
since the ISFETs are rinsed in 4 M NaCI, a 
monolayer coverage seems most plausible. Due 
to the small size of the protamine molecules 
(MW 4000), the protamine layer will be very 
thin; this makes it acceptable to assume that the 
immobilization of a protamine layer can be 
described as a modification of the surface charge 
of the ISFET. The ion-step response can therefore 
be described in the same way as the ion-step 
response of a bare ISFET, but with a different 
surface charge density, or, and point of zero 
charge, pHpzc. Therefore, the contribution of so- 
called membrane ffects, which were described 
in a previous description of the heparin sensor 
(Van Kerkhof et al., 1993), can be neglected. 
These effects include a changing Donnan potential 
at the protamine-solution interface, and a tempor- 
ary increase in the pH inside the protamine layer 
as a result of an uptake of protons by the 
protamine molecules induced by the stepwise 
increase in the electrolyte concentration. 
The measured ion-step response of an ISFET 
with a protamine layer, as shown in Fig. 2, curve 
2, supports the assumption to describe the effect 
of a protamine layer coverage as a surface 
modification. The ion-step has a smaller ampli- 
tude due to the positive charge of the protamine, 
compensating a part of the negative charge of 
the Ta205, but the time constants of the ion- 
step responses hown in Fig. 2 are about the 
same. This is shown in Fig. 8, where the responses 
of Fig. 2 are shown again but in this case are 
normalized to an amplitude of 1. It can be seen 
that the time constants are all comparable, 
including those of curve 3, which represents the 
response after incubation in heparin. Apparently, 
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Fig. 8. The same ion-step responses as in Fig. 2 but 
here normalized to the amplitude. Curve 1 is the 
response of a bare ISFET, curve 2 of an ISFET with 
a protamine layer and curve 3 the response after 
incubation in a heparin solution. 
the binding of heparin can still be described as 
a modification of the surface charge. If the 
previously mentioned membrane ffects should 
contribute to the ion-step response, this would 
certainly influence the time constants of the ion- 
step response of the ISFET. It should be noted 
that curve 1 was recorded in solutions that were 
buffered with 0.2 mM HEPES, of which the 
buffer capacity differs a little from the solutions 
buffered with 0.1 mM phosphate buffer used for 
recording curve 2 and 3. Because the pH was 
not exactly the same in both ion-step solutions, 
curve 2 and 3 do not return to 0 mV for t ~ 0¢. 
The amplitude of the ion-step response of an 
ISFET with a protamine layer is typically 9 mV 
(Fig. 2, curve 2). If it is also assumed in this 
case that the response reaches 54% of its 
maximum, as described by eqn. 4, a value of 
17 mV is obtained for A~max. Because the 
binding of the protamine results in a decrease in 
the absolute value of the surface potential ~,  
the value for the ratio Cdll/Cdl2 is also changed 
(see Fig. 7). From eqn. 4 and Fig. 7, it can be 
calculated that the new ratio Ca,/Cd~2 is 0-69, 
which corresponds to a potential ~1 (at 10 mM) 
of -55  mV. This potential results in a surface 
charge of -0.70 x 10 -6  C/cm 2, or 4-4 x 1012 
negatively charged groups per cm 2. With respect 
to a bare ISFET, the net surface charge is 
therefore decreased from 18-7 to 4-4 x 1012 
negatively charged groups per cm 2. This means 
that the adsorbed protamine contributes to a 
positive charge density of 14-5 × 1012 groups per 
cm 2. According to the amino acid content of 
protamine (Cundall et al., 1982) a molecular 
charge of +20 can be assumed, which yields a 
coverage of 7 x 10 -3 molecules per nm 2. This 
indicates that the protamine layer is not a dense 
layer, which indicates that the Ta205 surface is 
not completely covered with protamine. 
The results of the measurements of heparin 
concentrations in PBS show that four different 
ISFETs behave in virtually the same way with 
respect o the heparin concentration i PBS, as is 
shown in Table 1 (ISFET D at another pH, using 
another heparin). The offsets fall within the 
accuracy of the measurement of AA (mean value 
-+0-4 mV) and the slopes are almost equal. Accord- 
ing to the accuracy of AA (-+0-4 mV), the accuracy 
in the measurement of the heparin concentration 
in PBS should be -+0.04 Units/ml (using a mean 
slope of 11.1 mV.Unit-l.ml-~). However, the 
curve fit does not include all data points within 
the accuracy as given by the error bars. A possible 
cause for this extra inaccuracy might be found in 
the procedure. During the two mins incubation 
time, the sample is not stirred; this makes the 
affinity reaction at the surface very sensitive for 
convection in the solution, to which no special 
attention was paid. Moreover, the incubation is 
manually timed, which introduces an estimated 
error of about 5 s (4%). 
The interaction of heparin with a protamine 
loaded surface has been described by a Langmuir 
adsorption model (Kim et al., 1992). As a function 
of time, Kim et al., found a rapid increase in the 
heparin concentration at the surface during the 
first 10 mins, followed by an asymptotic approach 
to a steady state value. It can therefore be 
concluded that during the 2 mins of incubation 
time used in our procedure, no equilibrium or 
steady state value can have been reached. There- 
fore, the binding to the ISFET cannot be described 
by a Langmuir adsorption model, as is also obvious 
from the linear relation between the heparin 
concentration and AA. More experiments will be 
needed to study the binding of heparin to the 
protamine treated ISFET as a function of time, 
which makes it possible to optimize the incubation 
time. The observation that the amount of bound 
heparin increases rapidly during the first minutes 
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indicates that it is important to time the incubation 
period accurately. 
The measurements in normal blood plasma 
show a significant offset that is probably caused 
by a non-specific interaction of plasma compo- 
nents with the ISFET surface. Because it has 
been reasoned that the coverage of protamine is
not very dense, the non-specific nteraction might 
include interaction with protamine molecules, as 
well as adsorption on "free" Ta205. This non- 
specific interaction reduces the detection limit of 
heparin in plasma to about 0.25 Units/ml. A more 
dense coverage of the surface with protamine, for 
instance by covalently coupling the protamine 
to the surface, might reduce the non-specific 
adsorption on the Ta205 surface and therefore 
reduce the offset and improve the detection 
limit. Another difference in comparison with the 
measurement of the heparin concentration in PBS 
is the slope of the linear curve fit corresponding 
to the relation between AA and the heparin 
concentration, which is significantly smaller in 
the case of measurements in plasma. A possible 
explanation would be a smaller amount of heparin 
bound to the protamine during the incubation 
time of 2 mins and/or an attempt by heparin- 
binding proteins, immobilized at the ISFET 
surface together with the heparin, to compensate 
the charge of the heparin molecules. It is known 
that protamine is able to bind all possible active 
heparin molecules, and protamine has successfully 
been used to separate all active heparin from 
plasma samples (Kim et al., 1992). The kinetics 
of heparin in plasma could be different because 
of binding to proteins, which might reduce the 
amount of bound heparin during the 2 min. 
incubation time. Further esearch is necessary in
order to understand the exact mechanism. This 
includes the observation that the slopes of the 
linear curve fit corresponding to the measurement 
in plasma re different for the three ISFETs, while 
the slopes of the linear fit of the measurements in 
PBS are almost alike. 
The accuracy of the measured heparin concen- 
tration in plasma, according to the accuracy in 
AA, is 0.07 Units/ml for ISFET A, presented in 
Fig. 4 and 0.08 Units/ml for ISFET D, presented 
in Fig. 5. In these cases an extra inaccuracy 
might also be caused by the procedure, as 
explained earlier. 
Measurements of the heparin concentration i  
the patient plasma samples, as shown in Table 
2, show that in 9 out of 13 samples the added 
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amount of 0.5 Units/ml was correctly measured 
within the accuracy of the ISFET used (---0.08 
Units/ml). In these cases the calibration curve, 
which was recorded in normal plasma, could be 
used to determine the concentration in the 
individual plasma samples. The measured increase 
in the concentration i the four other samples 
was smaller than 0.5 Units/ml. Apparently the 
calibration curve obtained from measurements in 
normal plasma cannot be used in these cases. It 
is unclear which effects cause this difference; 
more specific experiments will be needed to 
investigate these effects. 
From Fig. 6 it is obvious that there is no direct 
relation between the heparin concentration and 
the APTT. This finding is not surprising because 
the APTT is dependent on several other para- 
meters (e.g. the concentration f AtlII and other 
clotting factors) that may vary from one patient 
to another. The therapeutic range for the APTT 
as used in the MST hospital has been defined as 
70 to 120 sec (normal values 25-35 sec). From 
Fig. 6 it can be seen that some of the plasma 
samples how clotting times within the therapeutic 
range whereas the heparin concentration appears 
to be >1-0 Units/ml. In another case the APTI" 
clearly exceeds the therapeutic range (156 sec) 
whereas the heparin concentration appears to be 
only 0-85 Units/ml. These results support the 
statement that the APTT is not a suitable assay 
with which to monitor heparin concentrations. 
Jaques et al., (1990) also determined absolute 
heparin concentrations i  patient plasma samples 
and plotted the APTr as function of the heparin 
concentration resulting in a plot similar to Fig. 
6, in which no relation could be determined. The 
heparin concentration was determined by first 
separating the heparin from the plasma followed 
by microelectrophoresis to determine the absolute 
amount (Jaques et al., 1990). In this context, it 
would be interesting to compare the heparin 
concentration as measured with the heparin 
sensor system described in this paper, with the 
result of a specific chromogenic substrate test 
that uses additional AtlII and gives a result 
which is related to the concentration of active 
heparin molecules. 
In this paper a heparin sensor system has been 
described that can determine absolute heparin 
concentrations i  blood plasma between 0.25 and 
2.0 Units/ml with an accuracy of ---0.08 Units/ 
ml. A detection limit of 0.25 Units/ml in blood 
plasma corresponds to about 13.3 x 10 -8 mol/1 
Biosensors & Bioelectronics ISFET based heparin sensor 
assuming an average molecular weight of 15 000 
and a value of 8 ~g per unit.* With respect o 
the heparin sensor that uses a porous membrane 
on top of the ISFET, as described earlier (Van 
Kerkhof et al., 1993), the non-specific interactions 
with other plasma components is significantly 
reduced. The incubation time is also reduced 
from 15 to 2 mins. More experiments are needed 
to study the behaviour of the sensor in individual 
plasma samples. The specifications of the sensor 
system can still be optimized by establishing a
higher degree of coverage of the Ta205 surface 
with protamine, which might reduce the non- 
specific interactions of other plasma components 
and increase the sensitivity to heparin concen- 
trations. The procedure can be optimized by a 
more accurate timing of the incubation time and 
by stirring the sample during incubation. 
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